Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

161. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis

Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis You J H, Lee A C, Wong S C, Chan F K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared standard-dose histamine-2 receptor antagonist (H2RA), low-dose proton-pump inhibitor (PPI) and standard-dose PPI as maintenance therapy in patients with gastrooesophageal reflux disease (GERD). The

NHS Economic Evaluation Database.2003

162. Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer

Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Abdulwadud O (...) . Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 11 Authors' objectives This aim of this critical appraisal was to assess the effectiveness of proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anti-Ulcer Agents; Peptic Ulcer /drug therapy; Proton Pumps Language Published English Country

Health Technology Assessment (HTA) Database.2002

163. The efficacy of proton pump inhibitors in adults with functional dyspepsia

The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia The efficacy of proton pump inhibitors in adults with functional dyspepsia Shiau J Y, Shukla V K, Dube C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shiau J Y, Shukla V K, Dube C (...) . The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 30 Authors' objectives Primary objective: To determine the efficacy of PPIs in the reduction of symptoms in adults with functional dyspepsia compared with placebo, prokinetic agents and H2-antagonists. Secondary objectives: - to determine if the effect of PPIs differs between symptom subgroups (dysmotility-like, or ulcer-like) in functional

Health Technology Assessment (HTA) Database.2002

164. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Are proton pump inhibitors the first choice for acute treatment of gastric ulcers: a meta analysis of randomized clinical trials Salas M, Ward A, Caro J Authors' objectives To compare gastric ulcer healing rates for patients treated (...) with a proton-pump inhibitor (PPI), an histamine 2-receptor antagonist or placebo. Searching MEDLINE, and the Cochrane Library were searched using the following keywords: 'proton pump inhibitors', 'PPI', 'rabeprazole', 'omeprazole' 'esomeprazole', 'lansoprazole' 'pantoprazole', 'ranitidine'; 'healing rates', 'gastric ulcer', 'stomach ulcer', 'gastric ulcer disease', 'peptic ulcer', 'peptic related disorders'; and 'clinical trials', 'randomized clinical trials' and 'multicenter studies'. In addition, medical journals were

DARE.2002

165. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis

Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis Edwards S J, Lind T, Lundell L Authors' objectives To compare the efficacy of lansoprazole with all other proton-pump inhibitors (PPIs) in the maintenance of healed reflux oesophagitis, through a systematic review (...) of randomised controlled trials (RCTs). Searching EMBASE, MEDLINE and AstraZeneca's internal database were searched for abstracts and full papers. The searches were completed in November 2001. The searches used the basic structure of: (1) terms for gastroesophageal reflux disease or oesophagitis, maintenance treatment and PPIs; and (2) all comparisons found between LAN 15 once daily or LAN 30 once daily and any dose of any other PPI. Study selection Study designs of evaluations included in the review Only

DARE.2002

166. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis Vallve M, Vergara M, Gisbert J P, Calvet X Authors' objectives To compare the efficacy of a single versus double dose (...) of a proton-pump inhibitor (PPI) in triple therapy for Helicobacter pylori (H. pylori) infection. Searching MEDLINE was searched in June 2001 for studies reported in English, French or Spanish. The search terms used were reported. Abstracts submitted to the American Gastroenterological Association congresses between 1995 and 2001, and abstracts obtained from the European Helicobacter pylori Study Group congresses between 1996 and 2001 dealing with H. pylori treatment, were handsearched. The reference lists of retrieved

DARE.2002

167. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis

Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Plumb J M, Edwards S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of esomeprazole (40 mg), a proton-pump inhibitor (PPI), in the treatment of gastro-oesophageal reflux disease (GORD). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients requiring treatment for GORD

NHS Economic Evaluation Database.2002

168. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand (...) oesophagitis in the UK. CRD COMMENTARY - Selection of comparators The authors justified the choice of the comparators. OME-CONT represented conventional care, while OME-INT was included to cover all possible treatment strategies for patients with GORD without oesophagitis. The authors noted that other treatment options for GORD were lifestyle modifications, antacids, alginates, histamine H2 antagonists, and various PPIs. However, several studies showed that PPIs were significantly more effective

NHS Economic Evaluation Database.2002

170. Proton pump inhibitors update

Proton pump inhibitors update Proton pump inhibitors update Proton pump inhibitors update Halas C Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Halas C. Proton pump inhibitors update. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new (...) . Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Digestive System Diseases; Proton Pump Inhibitors Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu

Health Technology Assessment (HTA) Database.2001

171. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

DARE.2001

172. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis

Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis Edwards S J, Lind T, Lundell L Authors' objectives To compare the effectiveness of esomeprazole with the recommended dose of proton-pump inhibitors (PPIs) in the healing of reflux oesophagitis, using omeprazole as a common (...) comparator. Searching EMBASE, MEDLINE, BIOSIS Previews and AstraZeneca's internal database were searched in December 2000. The search terms and strategy are reported in detail in the review. Study selection Study designs of evaluations included in the review The review specified randomised controlled trials (RCTs) with omeprazole (20 mg). Specific interventions included in the review Direct comparisons of any currently UK-licensed PPI with 20 mg omeprazole. The PPIs included in the review were

DARE.2001

173. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers

Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers Zed P J, Loewen P S, Slavik R S, Marra C A Authors' objectives To evaluate the efficacy of proton-pump inhibitors (PPIs), compared with placebo and histamine-receptor antagonists (H2RAs), for reducing the incidence of rebleeding, surgery and death in acute (...) gastrointestinal bleeding (GIB) associated with peptic ulcer disease. Searching MEDLINE, EMBASE and PREMEDLINE were searched systematically from 1966 to September 2000 for literature in the English language. The search terms included 'gastrointestinal', 'bleeding', 'hemorrhage', 'proton-pump inhibitor', 'omeprazole', 'pantoprazole', 'lansoprazole' and 'rebeprazole'. A manual search of the references from retrieved studies was also performed. Study selection Study designs of evaluations included in the review

DARE.2001

174. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori (...) infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Janssen M J, Van Oijen A H, Verbeek A L, Jansen J B, De Boer W A Authors' objectives To evaluate whether there is a difference in the efficacy between triple therapies with proton-pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus clarithromycin and either amoxicillin or a nitroimidazole, for the treatment of Helicobacter pylori (H. pylori) infection. Searching

DARE.2001

175. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer

Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Gisbert J P, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares J M Authors' objectives To evaluate whether proton-pump inhibitors are more effective than H2 (...) -antagonists (H2-A) for the treatment of bleeding peptic ulcer. Searching MEDLINE (via PubMed) was searched up to January 2000 using the keywords 'bleeding', 'proton pump inhibitor', 'peptic ulcer, and each of the drug names. The references of reviews and the retrieved articles were also examined. Study selection Study designs of evaluations included in the review Only randomised controlled trials (RCTs) were eligible. Specific interventions included in the review Trials that compared an H2-A (cimetidine

DARE.2001

176. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms

Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms Raisch D W, Klaurens L M, Hayden C, Malagon I, Pulliam G, Fass R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two proton-pump inhibitors, lansoprazole and omeprazole, were studied. No further details were given. Type of intervention Other: Impact of a formulary change that concerned treatments. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients in the study setting who

NHS Economic Evaluation Database.2001

177. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. BACKGROUND: Heartburn affects 25% of the adult population on a monthly basis and represents the core symptom of gastro-oesophageal reflux disease (GORD). Treatment is readily available and puts a large demand on healthcare budgets. Research in the past has focused largely on the treatment of oesophagitis. A majority (...) of GORD patients show no endoscopic abnormalities and in daily practice most patients are treated empirically. OBJECTIVES: Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in the empirical treatment of GORD and the treatment of endoscopy negative reflux disease (ENRD). SEARCH STRATEGY: Electronic searches were performed of the Cochrane Controlled Trials Register, MEDLINE and EMBASE. Bibliographies were

Cochrane2001

178. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review

The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review Bustamante M, Stollman N Authors' objectives To perform a systematic review of all randomised controlled trials (RCTs), performed between 1990 and 1998, evaluating proton-pump inhibitors (PPIs) in patients with acute ulcer bleeding in the upper (...) selection Study designs of evaluations included in the review RCTs were included. Non-randomised trials, comparisons between medical and endoscopic treatments, and those trials evaluating only intragastric pH while not reporting the primary outcomes, were excluded. Specific interventions included in the review PPIs, namely omeprazole and lansoprazole in varying dosages and treatment regimens, compared with treatment with either mannitol (placebo), somatostatin, or H-2 receptor antagonists (H2RAs

DARE.2000

179. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies van Oijen A H, Verbeek A L, Jansen J B, de Boer W A Authors' objectives (...) To compare treatment of Helicobacter pylori infection with ranitidine bismuth citrate- and proton pump inhibitor-based triple therapies. Searching The authors searched MEDLINE and Current Contents, and manually reviewed abstracts submitted to meetings of the American Gastroenterological Association (Digestive Disease and the United European Gastroenterology weeks) and the European Helicobacter Study Group, for the period 1996 to 1999. Study selection Study designs of evaluations included in the review

DARE.2000

180. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating (...) ', 'clarithromycin', 'amoxycillin', 'omeprazole', 'lansoprazole', 'pantoprazole', 'proton pump inhibitor' and 'triple' (titles). Additional material was obtained by examining references of retrieved articles and reviews on H. pylori treatment, and by manually searching abstracts submitted to the American Gastroenterological Association congresses (1995 to 1998) and the European Helicobacter pylori Study Group congresses on H. pylori treatment (1996 to 1998). Study selection Study designs of evaluations included

DARE.2000